ArticleBreast cancer research and treatment2026
The value of innovation in breast cancer treatment: real option value of olaparib for first-line treatment of gBRCA-mutated HER2 negative metastatic breast cancer.
Cynthia L Gong et al.PubMed ↗Publisher ↗
No numbers read from the abstract.